Skip to content

Perspective Therapeutics CATX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$228.35M
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$0
Immunome logo
ImmunomeIMNM
$229K+7.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0-100%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$0-100%
uniQure logo
uniQureQURE
$550K+246%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's stock issuance proceeds?
Perspective Therapeutics (CATX) reported stock issuance proceeds of $290K in Q1 2026.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.